Curis targets accelerated approval for emavusertib in PCNSL with 12-18 month enrollment timeline

Stock Information for Curis Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Curis Inc.

Curis to Present at Upcoming Healthcare Conference in April
Curis Provides Fourth Quarter 2024 Business Update
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
Curis Announces Additional Data from TakeAim Leukemia Study
Curis Provides Third Quarter 2024 Business Update
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement
Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.